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Lymphomas represent a wide group of heterogenic diseases with diﬀerent biological and clinical behavior. The underlying
microenvironment-speciﬁc composition seems to play an essential role in this scenario, harboring the ability to develop successful
immune responses or, on the contrary, leading to immune evasion and even promotion of tumor growth. Depending on
surrounding lymphoid inﬁltrates, lymphomas may have diﬀerent prognosis. Moreover, recent evidences have emerged that
confer a signiﬁcant impact of main lymphoma’s treatment over microenvironment, with clinical consequences. In this review,
we summarize these concepts from a pathological and clinical perspective. Also, the state of the art of lymphoma’s anti-idiotype
vaccine development is revised, highlighting the situations where this strategy has proven to be successful and eventual clues to
obtain better results in the future.
1.Introduction
Tumors are in permanent state of chronic inﬂammation,
and lymphoproliferative syndromes are not only a collection
of tumoral cells or a simple genetic disease. Tumoral cells
may give and receive instructions from other structural
components, the tumor microenvironment, which is com-
posed by extracellular matrix, stromal cells, neoangiogenic
vessels and overall, the cells and cytokines that constitute
the tumoral immune response. These elements constitute a
complex signalling network where a delicate balance exists
between microenvironment and tumoral cells. The products
of mutated or deregulated genes contribute to the growth
and invasion of tumoral cells, as well as to the expression of
proteins with the ability to stimulate the immune response.
The immunogenic capacity of the tumor can be evaluated
by means of the study of the reactive inﬁltration, which
is mainly composed by innate immune cells, especially
macrophages, also granulocytes, eosinophils and mast cells,
and adaptive immune cells, especially cytotoxic T cells—
CTLs-, the most important suppressor of tumoral growth
and target for vaccine approaches.
The hypothesis of immunesurveillance postulates that
one of the principal functions of the immune system would
be recognizing neoplastic cells and eliminating them before
they form tumors [1]. This aﬃrmation implies that in the
absence of an eﬀective immune system there is a high risk
of developing cancer. Truly, there is evidence involving the
immune system in the protection from certain tumors, espe-
cially those associated with viral infections, tumors related
with elderly, transplanted and immunosuppressed patients,
and those lymphomas associated with Epstein-Barr virus
(EBV), Kaposi’s sarcoma, and human immunodeﬁciency
virus (HIV).
Immune system is a nonlinear complex system, and its
main function in cancer is acting as an eﬀective suppressive2 Journal of Biomedicine and Biotechnology
system of tumors. However, as it occurs in the immunology
of infectious diseases, an adequate immune response with
enough magnitude to eradicate the microorganism or
harmful pathogen is necessary. Nevertheless, the system
can behave in an ineﬀective manner, as the appearance
of tumors in immunocompetent population shows. So,
along with the concept of immunosurveillance as immune
defensive process, the concept of immunostimulation also
arises [2], meaning that the immune response might not
only be ineﬀective but it might contribute actively to
tumoral progression. Among diﬀerent molecular distinctive
alterations of the lymphoproliferative syndromes, the role
of the microenvironment has been studied extensively, and
lymphocytes (cytotoxic T cells—CTL- and native killer—
NK-), macrophages, dendritic cells, and neutrophils con-
stitute potential eﬀectors of the antitumoral immunity.
Nevertheless, in the last few years a huge amount of evidence
has emerged suggesting that these cells can also promote the
growth and the development of the neoplasia, and that the
immune system not only can aﬀect the tumor, but the tumor
itself may also alter the host immune system.
The ability of the immune system to act as a double-edge
weapon, protective or stimulating, indicates that tumoral
clearance requires the eﬀective coordination of the diﬀerent
elements of the immune system in an appropriate balance
in quantity and quality. Therefore, current cancer research
in lymphoproliferative syndromes and other tumors aims to
develop methods to increase the eﬀectiveness of host anti-
tumor immune response. This inevitably leads to consider
tumors as more than an accumulation of neoplastic cells;
they might be more properly considered as a functional
tissue immunologically mediated and formed by a com-
plex tissue network in which neoangiogenesis, inﬁltrating
immune competent cells, stromal cells, and a diﬀerenti-
ated and speciﬁc extracellular matrix constitute the tumor
microenvironment with the capacity of regulating cancer
development [3]. The interplay between the host immune
system,malignantcells,andallothercomponentsoftumoral
stroma determine proliferation, invasion, angiogenesis, and
remodelling of extracellular matrix and metastasis.
2.CellularMicroenvironmentand
Hematopoiesis
Lymphoid neoplasms are functionally connected tissues
dependentonthemicroenvironment,determiningmorphol-
ogy and tumor classiﬁcation, clinical behaviour, prognosis,
and immune response to the tumor [4]. Perhaps one of
the greatest exponents of the maxim that tumors constitute
caricatures of normal tissues from which they arise might
be the lymphoproliferative syndromes. In physiological con-
ditions, the production of cellular elements corresponding
to the immune system is an elaborated process, into which
a series of main cells evolve in a sequential way, in a
process of diﬀerentiation of each of the hematopoietic
series. Its shortcomings are implied in the pathogenesis of
hematological malignancies [5].
The hematopoietic microenvironment is constituted by a
three-dimensional complex and highly organized structure,
which serves to regulate the location, proliferation, and
function of the hematopoietic cells. This is established by
stromal cells, extracellular matrix (ECM), cytokines, and
chemokines. Among stromal cells, there are macrophages—
derived from hematopoietic stem cells, ﬁbroblasts,
adipocytes, and osteoblasts. All of them are derived
from mesenchymal stem cells in the bone marrow and from
immature myeloid cells in the stromal tumor, along with
the endothelia of the neoangiogenic tumor microvessels.
The hematopoietic microenvironment not only has great
importance in the physiology of hematopoiesis and the
physiopathology of some leukaemia, but also in the
formation of the intratumoral cell microenvironment,
which structure corresponds to the ECM. ECM represents
a biophysical ﬁlter that oﬀers protection, nutrition, and cell
innervation, giving way for immune response, angiogenesis,
ﬁbrosis, and tisular regeneration. Its disruption supposes a
functional loss for nutrition, elimination, cell denervation,
regenerative capacity, and wound healing. This also causes
the loss of the immune response to pathogens, tumor cells,
and toxins.
Stromal tumor cells derive from progenitors of the bone
marrow, which are mobilized across the circulation until
joining the tumor microenvironment [6], where they will
developacrossdiﬀerentcellularlinesinendotelia,ﬁbroblasts,
histiocytes, and macrophages and ﬁnally constitute the
tumoral stroma. Tumoral microenvironment is involved in
the regulation of tumoral cell growth and the metastatic
potential of the tumor, so it is determinant in the response
to treatment [7]. The collaboration of one of these cells
in particular, the macrophage, turns out to be essential in
the process of migration, invasion, and tumor metastasis
[8]. It seems that stem cells derived from the bone marrow
represent the precursors of metastasis in distant sites, being
those in charge to activate a suitable microenvironment,
preparing an ideal niche to receive the tumoral cells [9].
Myeloid cells, with CTL suppressive activity, have a special
importance because they are recruited by the soluble factors
liberated by the proper tumor [10]. There, and in the shape
of intratumoral inﬂammatory monocytes, CD11b+ exert
their powerful immunosuppressive action in a multistep
process that could be interfered in each single step with the
subsequent restoration of immune reactivity.
3. AntitumoralImmunity
Tumor cells can express strange molecules recognized by
the immune system and the expression patterns of these
antigens vary among diﬀerent tumors. These tumor antigens
can be tumor-speciﬁc antigens (TSA), which are exclusively
expressed in tumor cells and easily evoke immune responses;
characteristic tumor antigens are TSA expressed only in
one or a few tumor clones, harbouring peculiar typical
mutationsofthesetumors;tumor-associatedantigens(TAA)
expressed both in normal and tumoral cells are often unable
to induce immune response owed to tolerance mechanisms.
Finally viral antigens represent viral strange tumor proteins
produced by oncogenic virus [11]. Tumor antigens recog-
nized by T cells (generally CD8+ lymphocytes) represent theJournal of Biomedicine and Biotechnology 3
principal target of antitumoral immunity and are presented
by MHC class I molecules; that is to say, that tumoral
cells behave as antigen presenting cells (APC), presenting
their own antigens to T cells. Naturally, professional APC
can also present antigens to CD4+ lymphocytes through
MHC class II molecules. Tumors can be destroyed by
means of speciﬁc CTL and an increase in tumoral immuno-
genicity is accompanied by the speciﬁc rejection of the
tumor.
Most tumor antigens identiﬁed by speciﬁc CTL are
products of aberrant gene expression and, surprisingly, are
not mutated. Products of oncogenes and mutated tumor
suppressor genes may also be presented in association with
MHC class I and/or class II. Both CD4+ and CD8+ Tc e l l s
can respond to the products of these genes such as mutated
ras gene, p53 and bcr-abl; however, it appears that these
responses are poorly protective. Other tumor antigens are
encoded by both RNA and DNA viruses that are implicated
in tumor development. Tumor cells synthesize and process
viral peptide complexes that are presented bound to MHC
class I, and therefore stimulate speciﬁc T cell responses.
These antigens encoded by viruses are not tumor speciﬁc but
aresharedbyalltumorsinducedbythesametypeofvirus.In
particular, the protective function of the immune system in
controlling virus-induced tumor DNA is given by the high
frequency of these tumors in immunosuppressed patients,
such as EBV-associated lymphoma.
Eﬀector systems of tumoral immunity are varied and
exert diﬀerent mechanisms of action. The main elements are
T cells and especially CD8+ cytotoxic T lymphocytes (CTLs)
that destroy tumor cells via the triggering of apoptosis,
and providing eﬀective antitumor immunity in vivo. They
are predominantly CD8 and carry out their function of
surveillance by means of the recognition and destruction of
potentially malignant cells, which express peptids derived
from mutated cellular proteins or oncogenic viral proteins,
presented in aﬃliation to MHC class I molecules. Tumor
inﬁltrating lymphocytes (TIL) are mononuclear cells that
inﬁltrate solid tumors. These include tumor-speciﬁc CTL.
The CD4+ helper T cells are traditionally considered as
noncytotoxic, although new evidence is emerging against
this concept [12]. Actually, at least four distinct CD4 T-
cells subsets have been described: Th1, Th2, Th17, and Treg
cells, each one with a unique cytokine secretion pattern
and function [13]. Of course one of their primary roles
is providing cytokines for the development of CTL, in
addition to being able to secrete TNF and IFN-gamma,
which can increase the expression of MHC class I by the
tumor cell and therefore increase its sensitivity to CTL lysis.
Immunoregulatory cytokines such as IL-10 and TGF-beta
play an important role in immune tolerance, and it seems
that suppressor eﬀect of T CD4+CD25+ is independent of
cytokines.
Among natural cytotoxic cells, natural killer cells (NK
cells) can be activated directly by contact with the tumor
or as a result of the stimulus provided by cytokines such
as interferons, TNF, IL-2, and IL-12, released by tumor-
speciﬁc T lymphocytes and macrophages; therefore, their
activity is endowed with some degree of speciﬁcity. In
addition,lymphokine-activatedkillercells(LAK)areagroup
of NK cells derived from peripheral blood cells or TIL
in patients with high concentrations of IL-2 and show
a high capacity, nonspeciﬁc in this case, to lyse tumor
cells.
Macrophages are cellular mediators capable of lysing
tumorcellsbyreleasingalargeamountoflysosomalenzymes
and reactive oxygen metabolites. Once activated they also
produce cytokines such as tumor necrosis factor (TNF)
that exerts its cytotoxic activity triggering apoptosis in a
similar way to that mediated by Fas; it has indirect eﬀects
on tumor vasculature and vascular thrombosis and produces
free radicals from which normal cells are protected by the
secretion of superoxide dismutase, but not tumoral cells.
Dendritic cells (DC) and other antigen presenting cells
(APC) are dispersed between tissues as sentinels or alarm
systems ready to detect the presence of foreign antigens.
While in the tumor microenvironment IL-12 production
tendstobesuppressed,resultinginadecreaseinTh1activity,
DCs represent probably the most important regulators of
na¨ ıve T cells, with a great capacity to produce and release
IL-12. In their process of polarization, DCs are under the
inﬂuence of inﬂammatory mediators such as prostaglandins
produced by macrophages, ﬁbroblasts, and tumor cells. A
newrouteofjunctionbetweeninnateandadaptiveimmunity
through the interaction between DC and NK cells has
been suggested [14]. Finally, it is believed that antibodies
are less important than the T cells to mediate antitumor
immune response. However, there are Ab responses specif-
ically against viral Ag, as in patients with EBV-associated
lymphomas.
The tumor microenvironment consists of a speciﬁc
mixture of immune cells that express a distinctive proﬁle for
eachtumortype[15],fromwhichtheeﬃcacyoftheimmune
response against the tumor is eventually derived. Especially
polynuclear neutrophils, dendritic cells, macrophages, NK
cells, and mast cells play an important functional role
in preneoplastic and tumoral tissues. Diﬀerences in gene
expression proﬁles of malignant cells in lymphoproliferative
syndromes do not always determine the aggressiveness of
the lymphoma, while recent contributions determine the
increasing importance role of cellular microenvironment in
prognosis and disease progression. Each phase of tumor
development progresses according to speciﬁc signals. So,
while the activation of the immune response in advanced
stages may be beneﬁcial to the host, its activation during
early stages can stimulate tumor development. Although
lymphoid cells inﬁltrating the tumors are often considered
as cytotoxic to tumor cells, these cells often contribute
to the oncogenic process, tumor growth, and dissemina-
tion. Speciﬁc cells are responsible for activating speciﬁc
processes within the tumor tissue, as occurs with mast
cells and tumor neovascularization. Dendritic cells and
macrophages may provide growth factors to malignant cells,
sometimes instigated by viral sequences from stromal cells
and not tumor cells themselves. The same cell in diﬀerent
microenvironments can act diﬀerently, as beﬁts its power of
dialogue and dynamic response to stimuli from the stromal
environment.4 Journal of Biomedicine and Biotechnology
4. Immune Response in Lymphoproliferative
Syndromes
Lymphoproliferative syndromes are mainly distinguished
by speciﬁc clinical factors and characteristic molecular
alterations of low- and high-growth fraction lymphomas.
Lymphomas with smaller fraction of growth include fol-
licular lymphoma (FL), marginal zone lymphoma (MZLs),
mantle cell lymphoma (MCL), and chronic lymphocytic
leukaemia B (B-CLL), which as a group share a paradoxical
combination of advanced clinical stages associated with a
low clinical aggressiveness. By contrast, lymphomas with
high-growth fraction, including diﬀuse large B cell lym-
phoma(DLBCL)andBurkittlymphoma(BL),arefrequently
associated with clinically localized stage but a high clinical
aggressiveness. Each of these groups appears to accumulate
speciﬁc molecular proliferative and apoptotic changes [16],
but diﬀerences in gene expression proﬁles of malignant
cells do not always determine the aggressiveness of the
lymphoma.
A wide repertoire of speciﬁc cell subpopulations consti-
tutes the tumor microenvironment of each lymphoprolifera-
tive syndrome [17], with important diagnostic, prognostic,
and therapeutic implications [4]( Table 1). The nature,
role, and speciﬁcity of eﬀector cells that are capable of
inhibiting the growth of T and B-cell lymphomas in vitro
and in vivo in immunocompetent individuals have been
studiedextensively.Thenumberandespeciallytheactivation
status of inﬁltrating cells appear to be independent of
the degree of malignancy in Hodgkin’s lymphoma and
various B and T cell non-Hodgkin’s lymphomas [18]. The
reactive microenvironment determines not only histological
morphology and immune phenotype, but also the clinical
outcome of lymphoproliferative syndromes. Some of them,
such as HL, slow growing tumor as FL, fast growing tumor as
DLBCL or T cell lymphomas, are going to be revised brieﬂy
in the next paragraphs (Table 1).
4.1.HodgkinLymphoma. Asiftumoralentitiesweresculpted
by the immune system, the presence of a characteristic
inﬂammatory background not only distinguishes Hodgkin
Lymphoma (HL) from other lymphomas, but even more,
thisisthemaincharacteristicthatmakesHLaseparateentity
itself allowing its diagnosis. Tumor cells of HL-PLN and the
TCRBCLarethesameorverysimilar,neverthelessweclassify
these two diseases diﬀerently depending on the accompany-
ing tumor microenvironment. Thus, HL and other germinal
centre-derived lymphomas can be diﬀerentiated through
their cellular microenvironment [19].
Regardless of the classic clinical and pathological fea-
tures, some studies have shown that the presence of activated
CTLs (granzyme B+) is associated with an unfavourable
follow up of HL patients [20]. There is a predominance
of activated CD4+ T cells in the background of the tumor
[21] and a high number of cytotoxic T lymphocytes [22]
around the Hodgkin/Reed Sternberg cells (H/RS). CD4+ T
cells produce Th2 cytokines that could contribute to local
suppression of the cellular immune response mediated by
Th1. However, the categorization of CD4+ T cells in Th1
and/or Th2 is an oversimpliﬁcation [23] as regulatory T
cells with CD4+CD25+ phenotype not only play a reg-
ulatory role of autoimmunity, but also have suppressive
eﬀects on the development of antigen-reactive lymphocytes
associated with the tumor [24]. Functional and molecular
characterization of these cells has been facilitated by the
identiﬁcation of markers such as FOXP3, which acts by
converting na¨ ıve T cells CD4+CD25− into the regulatory
phenotype CD4+CD25+ [25]. These regulatory T cells can
inhibit the production of IL-2 as well as upregulating the
expression of IL-2Ra (CD25), delaying or blocking the
activation of CD8+ cells and NK cells against tumor antigens
[26]. In HL, the immunosuppressive properties of regulatory
Tcellsappeartobeparticularlyimportantbecauseofitslarge
eﬀect on cellular cytotoxicity represented by CTLs and NK
cells. The presence of low numbers of FOXP3+ cells and a
consequent high rate of TIA-1+ cells in the inﬁltrate repre-
sents an independent prognostic factor negatively aﬀecting
the survival of the disease. Furthermore, when the disease
relapses and progresses, larger number of TIA-1+ cells and
lower proportion of FOXP3+ on the reactive background of
thetumorarealsopronetobeseen[27].Thereisasigniﬁcant
loss of intratumoral CD4+ T cells (an inversion of CD4/CD8
ratio) and a decrease of intratumoral activated CTLs in
HIV-infected HL patients [28]. All these data are of interest
due to the possibility to signiﬁcantly expand tumor-induced
CD4+ Tregs by the application of therapeutic cancer vaccines
[29].
A plausible explanation of the extensive inﬂammatory
inﬁltrate present in HL could be the secretion of a variety of
cytokines produced by both tumor cells and the surrounding
stromal tissue. H/RS cells produce and secrete high amounts
of chemokines, including TARC and MDC, which attract
lymphocytes expressing the CCR4 receptor [30]. In addition,
immune cells themselves can produce cytokines responsible
for proliferation and tumor survival.
Within the complexity of the interactions between
the inﬂammatory reaction and HL tumor cells, immune
cells present in the inﬁltrate can modulate apoptosis and
proliferation of tumor cells [31]. The antiapoptotic proﬁle
observed in H/RS cells is associated with a general increase
in inﬁltrating CD4+ T cells and a general decrease in
inﬁltrating CD8+ T lymphocytes, NK cells, and dendritic
cells. The progression of G1/S tumoral phase and the
high rate of proliferation are also strongly associated with
higher inﬁltration of the overall immune response against
the tumor [32]. These results point to the regulation of
proteins involved in apoptosis and proliferation of tumor
cells by direct interactions between these cells and the
surrounding inﬂammatory microenvironment. This opens
upnewapproachesforresearchandtreatmentofHLthrough
the modulation of host immune response.
4.2. An Example of Low-Grade B-NHL, Follicular Center Cell
Lymphoma (FL). FL is recognized as a disease of functional
B cells, in which T-cell costimulation is essential in the
maintenance and ongoing development of B-cell secondary
follicles [33, 34].Journal of Biomedicine and Biotechnology 5
Table 1: Type of immune inﬁltration in Lymphomas and prognosis.
Type of lymphoma Microenvironment Prognosis
HL
↑↑ activated CTLs (Granzyme B+) Unfavourable
↑↑ TIA-1+ cells
↓↓ FOXP3+ cells
FL
Type 1 immune response pattern Longer survival
↑↑ T lymphocytes and regulatory T cells (FOXP3+) Favourable outcome
Type 2 immune response pattern Shorter survival
↑↑ tumor-associated-macrophages (TAM, CD68+)a n dN Kc e l l s( C D 5 7 +)P o o r p r o g n o s i s
DLBCL
↑↑ activated CD4+ T cells, dendritic cells and macrophages Better prognosis
Inﬁltrate greater than 20% of CD4+ cells, including CD45RO+
↑↑ FOXP3+
Higher expression of Th1 than Th2
↓↓ IL-6 (Th2 response) during the ﬁrst weeks after the therapy Predict complete
remission
↓↓ TILs-CD8+, ↑↑ activated CTLs Poor prognosis
Ta n dN Kc e l l
↑↑ monocytes Poor prognosis
↓↓ FOXP3+ Unfavorable
ALCL
↑↑ Granzyme B+ Unfavorable
↑↑ Granzyme B+ and lack of expression of ALK Poor prognosis
Since the FL represents the tumoral counterpart of
germinal centre B cells and resembles its follicular archi-
tecture, the development of this lymphoma may be closely
linked to interactions with cellular components of the
microenvironment, including dendritic and Tcellsinside the
follicle. It is said that the relationships between tumoral cells
and microenvironment can follow three distinct patterns:
a loss of interconnection with the immune response to
the tumor, a dysfunctional environment, and a friendly,
regulated coexistence of the malignant and immune cells
[35]. FL seems a good example of the latter pattern, a disease
usually indolent and with a long median survival in which at
least 15% or greater may experience spontaneous remission,
sometimes after acute viral illness and with rapid responses
after vaccine therapy. In addition, tumor microenvironment
butnottumorcellscouldbethefundamentalkeytochoosing
the most appropriate chemotherapeutic regimen for these
patients [36].
Atmolecularlevel,survivalofpatientswithFLappearsto
correlate with the characteristics of nonmalignant immune
cells present in the tumor at diagnosis through two patterns
of gene expression [15] .T y p e1i m m u n er e s p o n s ep a t t e r n
is associated with longer survival and includes a complex
mixture of T cells and other immune cells, while type
2 pattern is associated with shorter survival and includes
genes that encode no markers of innate immune cells,
primarily macrophages. The diﬀerences in the biology of
the host immune response determine the clinical course and
prognosis of patients with LF, and not the genetic alterations
of the tumor cells themselves.
At cellular level, the relationship between cellular ele-
ments of speciﬁc and nonspeciﬁc cell-mediated immunity
implies that FL is an immunologically functional disease
in which an interaction between the tumor cells and the
functional composition of the microenvironment deter-
mines their clinical behaviour [37]. The general mechanisms
involved in FL tumor immunity have been principally
attributed to CD4+ Th e l p e rl y m p h o c y t e s ,C D 8 + cytotoxic
T-cells (CTLs), NK cells, and macrophages. The presence
of modulating FOXP3+ T-cells has also proved to have an
important role in the host immune response [38]. Taken
as a whole, the results of these studies have highlighted
the existence of two principal immune facts in which the
p r e s e n c eo fTl y m p h o c y t e sa n dr e g u l a t o r yTc e l l si sr e l a t e d
to a favorable outcome, whereas the presence of tumor-
associated macrophages (TAM) and NK cells is more usually
associated with a poor prognosis. Dysfunctional immune
proﬁles in the tumor microenvironment of FL seem to be
attributed to the state of functionality of regulatory T cells,
the presence of a particular subset of CD57+ cells, and the
reprogrammed immune cells such as TAMs [37, 38].
The favorable clinical impact of the high number of
Tregs in FL may be due to a direct inhibitory eﬀect
on neoplastic B-cells [39] and the inhibition of tumor-
inﬁltrating leukocytes that can facilitate tumor progression
by secreting various growth factors and proteases. However,
in epithelial carcinomas these cells correlated inversely with
clinical outcome [40], representing the dominant immune
escape mechanism early in the tumor progression but not
in late phases [41]. These diﬀerent behaviors seem to be
secondary to diﬀerent mechanisms of immune response
regulation from Tregs in FL and in solid tumors. Tregs
have numerous lymphoid targets, including CD8+ T cells,
B cells, NK cells, and dendritic cells. When the control of
the immune response is misguided, Tregs cells can induce
immunosuppressive mechanisms through the attenuation6 Journal of Biomedicine and Biotechnology
of tumor-speciﬁc CD8+ T-cell killing and restricted NKT
cells.
In addition to FOXP3+ Tregs cells, CD57+ cells appear to
represent another marker of general immune dysfunction in
FL[42].UnlikeTcellsandmacrophages,ahigherinﬁltration
of CD57+ cells appears to be related to unfavorable clinicobi-
ological factors in FL patients [38]. CD57 is expressed on NK
cells, one of the major eﬀector cells in cellular cytotoxicity
together with CTLs. The nonspeciﬁc inﬂammatory inﬁltrate
(CD57+ cells and CD68+ macrophages) seems to be mainly
involved in the control of growth and expansion of tumoral
cellswhereasthespeciﬁcimmuneinﬁltrate(CD4+ andCD8+
T lymphocytes) seems to be mainly involved in the host
immune response against the tumor and the main clinical
features. Both systems seem to emerge directly associated
with the capacity to disseminate tumoral cells, as shown by
the greater inﬁltration of T lymphocytes observed in low-
grade FL with spontaneous regression [43], the relatively low
absolute number of T cells observed on transformation [44],
and the role of na¨ ıve and memory T cells in downregulating
tumor proliferation rate [45].
Although in a non-restrictive cohort of FL patients
was considered, the presence of CD68+ TAM tended to be
associated with an indolent clinical behavior and longer
survival [46], CD68+ TAM appeared to be associated with
an unfavorable outcome for FL patients [47]. The speciﬁc
subsetsofactivatedmacrophagesevaluatedbytheexpression
of STAT1 may be considered as prototypic type 2 polarized
macrophages reprogrammed to induce in situ immune
suppression. TAMs seem to have a dual nature that appears
to be speciﬁc to the tumor type. Depending on the microen-
vironment, they may either exhibit antitumor cytotoxic
activity or facilitated tumor growth and progression while
reinforcing the Th2-biased immune response [48]. Polarized
M1andM2(oralternativelyactivated)macrophagesdiﬀerin
terms of receptor expression, eﬀector function, and cytokine
andchemokinesproduction.Regardlessoffunctionaldefects
or absence of activation, in most of the cases TAM do
not exhibit cytotoxic activity and facilitate tumor growth,
angiogenesis, and metastasis, that is, Th1 immunosuppres-
sive response. TAM products act in two manners to support
tumorprogression,ononehand,theysupporttumorgrowth
angiogenicity and extracellular matrix degradation, and on
the other hand, they suppress potential antitumor activities
[49].
4.3. An Example of High-Grade B-NHL, Diﬀuse Large B Cell
Lymphoma (DLBCL). Recent molecular studies show that
survival of patients with DLBCL is inﬂuenced by immune
cells, ﬁbrosis, and angiogenesis of tumor microenvironment
[50]. Stromal-1 signature genes encode components of
the extracellular matrix and antiangiogenic factors, while
stromal-2 signature genes encode markers of endothelial
cells and key regulators of angiogenesis. This survival model
reﬂects the character of nonmalignant cells in DLBCL,
including TAMs and myeloid-derived suppressor cells.
At immunophenotypical level, the component of non-
malignant inﬁltrate can vary among the diﬀerent subtypes
of DLBCL, with the greatest exponent provided by the
T cell/histiocyte rich B-cell lymphoma. The presence of
an increased number of activated CD4+ T cells [51]a s
well as dendritic cells and macrophages seems to predict a
better prognosis of DLBCL. The DLBCL negative for gene
expression of MHC II have few CD8+ T cells inﬁltrating the
tumor [52] and a high percentage of activated CTLs, both
of them representing a powerful adverse prognostic factor
[53]. A speciﬁc subgroup of patients with DLBCL deﬁned in
terms of host response has been identiﬁed [54]; in this type
ofresponse,anincreasedexpressionofNK/Tcell,monocyte-
macrophages, and dendritic cells (DCs) markers as well as
inﬂammatory mediators can be observed. Moreover, those
cases with an inﬁltrate greater than 20% of CD4+ cells,
including CD45RO+, show a trend towards better survival.
Although it is possible that the role of the microenvironment
as a whole can be dual, depending on the tumor, the patient,
and the functional status of the host immune system.
An eﬀective cytotoxic response represented by a dense
CTL inﬁltrate and numerous accompanying reactive cells
including a high number of FoxP3+ Treg cells seems to
be accompanied by better prognosis in DLBCL [55]. The
presence of interdigitating dendritic cells associated with
inﬁltrating T cells is involved in coordinating the immune
response. However, tumor cells also seem able to modulate
the maturation of dendritic cells so they can remove the
ability of these cells to process and present tumor antigens.
A higher expression of Th1 than Th2 response has also been
observed in patients who achieved complete remission [56],
and a signiﬁcant decrease in IL-6 (Th2 response) during the
ﬁrst weeks after therapy in patients with aggressive NHL
seems to predict complete remission [57]. In these patients, a
germinal center phenotype (bcl-6+/CD10+) is accompanied
by a lower level of circulating IL-6 compared to activated
phenotypes.
4.4. T and NK Cell Lymphomas. Frequently, in T-NHL,
the microenvironment cellularity represents the bulk of the
tumor, and the clinicobiological manifestations of disease
reﬂect a deregulated immune response rather than the eﬀect
of tumoral cells. In PTCL as well as in AITL, a follicular
helper T cell tumor, once again, there is not an associa-
tion between gene clusters and their histological subtypes
[58]. However, cells present in tumor microenvironment
promote tumorigenesis and suppress host immunity. T
cell lymphomas characteristically present a great number
of monocytes that promote survival of malignant cells
[59]. Another lymphoma characterized by the signiﬁcant
presence of reactive lymphocytes around tumor cells is
anaplastic large cell lymphoma (ALCL), where inﬁltration
of a high percentage of activated cytotoxic cells (Granzyme
B+) is an unfavorable prognostic marker [60], especially
when combined with the lack of expression of ALK. The
mechanismsbywhichtumorcellsescapetheCTLattackhave
been scarcely investigated, although among the postulated
mechanisms, the downregulation of MHC I molecules, the
expression of IL-10, the expression of FAS-L in tumor
cells, overexpression of Bcl-2, and also the expression
of PI9, an inhibitor of proteolytic activity of granzyme
B, have been considered [61]. The FoxP3+ Tregs cellsJournal of Biomedicine and Biotechnology 7
predicted improved clinical outcome in extranodal NK/T
lymphomas, whereas a decreased number of these cells are
more common in patients with poor performance status
[62].
Therapeutic Applications of Immune Response. The immune
system appears to be essential for therapeutic success if we
consider that it can eliminate deﬁnitively residual cancer
cells that remain after chemotherapy. In this sense, therapy
applied during tumor escape phase can inhibit suppressive
mechanisms of tumor-induced tolerance, boost T and/or
B cells, or stress tumor cells in such a way that tumor
cells become immunogenic and sensitive to lysis [63]. The
simple reduction of the tumor mass by chemotherapy or
surgical removal may also reduce its immunosuppressive
properties, reversing tumor-induced immune tolerance and
restoringtheantibody-andcell-mediatedimmuneresponses
[64].
On the relationship between the tumor and the immune
system, the immunosuppressive side eﬀects of massive
chemotherapy should be reevaluated. A bidirectional inter-
action between tumor and inﬂammatory/immune cells is
ultimately responsible for orchestrating the immunosup-
pressive network at the tumor site [65]. The manipulation
of one of these partners may consistently inﬂuence the
other. Looking for new modalities of cancer treatment, the
induction of a potent and speciﬁc immune system has been
described as a logical and reasonable strategy for controlling
tumor evolution. The diﬀerent strategies that have been used
to improve immunity against tumors include vaccination to
provide antigens to the patients’ immune system, providing
costimulatory signals on tumor cells, induction of cell death
with cytotoxic drugs, sustaining immune eﬀectors with NK,
NKT, or DC adjuvant, and improving eﬃciency of cross-
priming [66]. If anticancer immune responses dictate long-
term therapeutic success, then local signs of antigen priming
(DCs) or NK and T cell responses would correlate with
favorable responses.
In conclusion, diﬀerent entities of lymphoproliferative
syndromes, independently whether they are HL or NHL, B
or T cell lymphomas, and fast or slow growing tumours,
have speciﬁc patterns of immune responses associated with
their morphologic aspect, their immunophenotype, their
clinicobiologic course, outcome and the probable response
to the therapeutic drug used in their clinical management.
Among the nonspeciﬁc immune response, a clear distinction
can be made between activated and nonactivated CTL, with
diﬀerent signiﬁcance in various lymphomas [4] .T h e r ei sa
speciﬁc machinery to control the tumor microenvironment,
represented fundamentally by Treg cells, FoxP3+, CD57+
T cells, and TAMs. Chemotherapy can inhibit a tumor-
promoting immune reaction but may in fact be an example
of immunotherapy depressing mast cells and macrophages
that secrete factors with the ability of promoting tumor
growth. In the search of new modalities of lymphoma
treatment, the induction of a speciﬁc immune response
through eﬀective immunotherapy appears to be a promising
route of help for these patients and their clinicians.
5. Immune Effects of Antineoplastic Therapy in
Lymphoproliferative Syndromes
We will discuss new evidence about immune microenviron-
ment changes after antineoplastic treatment in lymphomas.
Lymphomas represent a wide group of heterogenic diseases
with diﬀerent clinical behaviours, and nowadays, the three
main options in lymphoma’s armamentarium remain to be
chemotherapy, radiotherapy, and passive immunotherapy
(monoclonal antibodies). All these treatments have a rele-
vant impact on the surrounding stroma and microenviron-
ment.
5.1. Chemotherapy—The Anthracyclines Model. Chemother-
apy remains the treatment modality of choice for most
lymphomas, especially in advanced stages. Diﬀerent cyto-
t o x i cd r u g sd e s t r o yt u m o rc e l l sb ya p o p t o s i s ,ap r o c e s s
mediated by the activation of caspases and exposure of
phosphatidylserine residues in the outer leaﬂet of the cell
[67]. Apoptosis destroys billions of cells in an adult lifetime
as a consequence of physiologic tissue renewal and cell
turnover without leading to any adverse inﬂammatory or
autoimmune phenomena. Thus, programmed cell death has
been traditionally considered as immunologically “bland”
or nonimmunogenic. However, this theoretical assumption
has not been conﬁrmed in basic and translational research.
Rather, it seems that apoptosis is a heterogeneous process,
that under some circumstances may lead to immuno-
genic eﬀects. Recent studies focus on apoptosis and tumor
suppressor pathways in cancer and suggest that some
chemotherapeutics may induce tumoral destruction which
improves cancer cell recognition by the immune system
[68, 69].
Anthracyclines remain one of the drugs of choice
against lymphoproliferative diseases for Hodgkin’s and Non-
Hodgkin’s Lymphomas and is included in most of the ﬁrst
line chemotherapy schedules. There is now clear evidence
that anthracyclines may promote apoptosis in cancer cells
with immunogenic eﬀects through several mechanisms
(Figure 1).
(1) Calreticulin. Anthracyclines facilitate the translocation
of intracytoplasmic protein calreticulin (CRT) to the cell
surface, inducing the apoptotic cell antigen presentation to
Antigen Presenting Cells (APCs), in particular dendritic cells
(DC), and stimulating speciﬁc antitumor T cell responses
[70].
(2) High-Mobility Group Box 1 (HMGB1). Another immu-
nogenic determinant of cell death is the pro-inﬂammatory
factor HMGB1. HMGB1 is a nuclear protein that is released
after necrotic cell death and, as recently reported, from dying
cells during late stage apoptosis. After cell death induced
by anthracyclines and alkylating agents, HMGB1 may be
released in the stroma and act as a neo-antigen representing
an immunogenic endogenous “danger signal”, initiating an
inﬂammatory response through binding Toll-Like Receptor8 Journal of Biomedicine and Biotechnology
4 (TLR4) on DC (but not other DC receptors, such as RAGE
or TLR2) [71]. MyD88 is one downstream eﬀector of TLR4,
and nowadays there is clear evidence which supports that
immunogenicity triggered by anthracyclines is exclusively
dependent on an intact TLR4-MyD88 signalling pathway
[72].
(3) DNA Damaging Agents. Alkylating chemotherapeutic
agents, such as cyclophosphamide, induce the expression of
NKG2D ligands. NKG2D acts as an activating receptor on
NK cells, γδ T cells, NKT cells, and memory CD8+ T cells,
givingraisetothepossibilitythatDNAdamageresponsemay
induce immune system activation [68, 73].
(4) Secondary Necrosis. Although not speciﬁc for anthracy-
clines, when massive chemotherapy cell destruction occurs,
the mechanisms of controlled apoptosis are overwhelmed
and a secondary necrosis occurs triggering an inﬂammatory
response mediated by the intracellular inﬂammation media-
tors release, as uric acid, heat shock proteins (HSP), and IL-
12 [74].
(5) Cross-Presentation. Cross-presentation is a mechanism
favouredbysomeantineoplasticdrugssuchasanthracyclines
or gemcitabine. These drugs allow tumor antigens to be
presented to MHC class I pathway through APCs, a pathway
previously thought to be restricted to class II pathway. This
mechanism allows tumor antigen presentation to both CD4
T and CD8 T cells which will subsequently identify and
destroy the remaining tumour cells [75], but paradoxically
apoptotic cells lead to secretion of VEGF that promote
the proliferation of endothelial cells and other survival
factors that stimulate extracellular matrix with many other
implications.
(6) Eradication of Tumor Cells by Chemotherapy. Immune-
inhibitory molecules released by tumor cells, such as
interleukin-10 (IL-10) or tumor growth factor-β (TGF-
β) which inhibit T cell activation, or IL-10, IL-6, and
vascular endothelial growth factor (VEGF), involved in the
maturation and diﬀerentiation of dendritic cells (DCs), are
downregulated as a result of the use of chemotherapy after
an eﬀective cell destruction [76].
Therefore, emerging evidence led Lake and Robinson
to announce a paradigm shift in the way of understanding
the eﬀects of chemotherapy on the surrounding stroma
[76, 77]. CT can induce a highly potent immune response by
increasing antigen (neoantigens) threshold and presentation
(via APCs), with enhancement of T-cell response and
generation of memory T cells. Other chemotherapeutics like
cyclophosphamide, etoposide, and taxanes (docetaxel and
paclitaxel)havealsoprovedtohaveanimmunogeniceﬀectin
preclinical models [78, 79]; however, evidence is scarce and
further investigation is required. These new concepts may
serve to consider chemotherapeutics like anthracyclines as
less empirical and more speciﬁc drugs, and then customizing
treatments taking into account its potential eﬀects on
microenvironment.
5.1.1. Dendritic Cells and GM-CSF. Among diﬀerent
molecules and cells activated as a result of immunogenic
cancer cell death mediated by chemotherapy, antigen
presenting cells (APCs), in particular dendritic cells
(DC), seem to play an essential role. This is particularly
true because tumor reactive T cells are often anergic
because of inappropriate antigen exposure or owed to
self-recognition. On the contrary, immunogenic tumor cell
death mediated by some chemotherapies is characterized by
a temporal sequence of events including early translocation
of calreticulin to the cell surface, and thereafter interaction
of CRT with multiple receptors on DC with apoptotic bodies
phagocytosis, release and exposure of heat shock proteins,
and late release of HMGB1 [68]. HMGB1 is able to bind
to the TLR4 receptor on DC, which allows tumor derived
antigens to be processed and presented along with MHC
and costimulatory molecules on the surface of DC [68, 69].
These mechanisms altogether serve to trigger DC-mediated
speciﬁc antitumor response, which may be enhanced by the
use of costimulatory molecules. Costimulatory molecules
provide additional or second signals for lymphocyte
activation beyond those provided through the antigen
receptor.
GM-CSF is one of the most important cytokines in
cancer microenvironment [80]. GM-CSF has pleiotropic
properties, including the mobilisation, diﬀerentiation, and
function of dendritic cells, possibly by reversing the host’s
immune tolerance to its own tumor associated antigens,
and by initiating (priming) immune responses for which
immunologic memory has not been established, that is,
activating the so-called na¨ ıve T cells. The proliferation of
na¨ ıvelymphocytesduringtheﬁrstencounterwithanantigen
(primary immune response) generates both eﬀector T and
B cells and memory T and B cells. Memory cells enable a
quantitatively and qualitatively superior secondary immune
response to be mounted after a subsequent encounter with
the same antigen [81].
GM-CSF has been studied in the clinical setting in
relapsed follicular lymphoma, along with Rituximab, show-
ing promising results. In a phase 2 trial, combination of
rituximab with GM-CSF attained 70% overall response
rate (ORR) and 39% complete response rate (CRR), which
comparesfavourablywithrituximabassingletherapyagainst
relapsed follicular lymphoma (CRR of 6%) [82]. This
synergism can be explained, at least in part, by the antibody-
dependentcellularcytotoxicity(ADCC)ofRituximab,which
is enhanced by GM-CSF [83]. Interestingly, a molecular sub-
study was executed, demonstrating that this immunotherapy
schedule increases the counts of numerous immune cells,
particularly monocytes and granulocytes. However, there
were no diﬀerences between CR and non-CR patients in the
mean and ratio pre- or postimmunotherapy counts [82].
Some groups argue that maybe a better way of analyzing the
impact of these therapeutic approaches would be determin-
ing the magnitude of accumulation of the eﬀector cells at
tumor sites, and not only blood levels, with semiquantitative
measures through radiolabeling autologous granulocytes or
mononuclear white blood cells with indium-111 labeled
oxine [84]. The latter would be a highly interesting approachJournal of Biomedicine and Biotechnology 9
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Figure 1: Immunogenic eﬀects of anthracyclines and radiation. CRT—Calreticulin; DC—Dendritic cell; CTL—Cytotoxic T lymphocytes;
TLR4—Toll-like receptor 4; HMGB1—High-mobility group box 1.
tomonitorimmuneresponseinvivo,especiallyifitcorrelates
with clinical eﬃcacy.
5.2. Radiotherapy. Radiation therapy has been the back-
bone of lymphoma’s treatment during decades. Though
indications have diminished in the last years, radiotherapy
still remains the treatment of choice for curative pur-
poses in localized low-grade non-Hodgkin’s lymphomas
and Hodgkin’s lymphoma, and even in high grade non-
Hodgkin’s lymphomas as a consolidation treatment after CT
in sites of initial bulky disease.
Intrinsic radiosensitivity of malignant lymphocytes is
extremely high; however, the underlying mechanisms which
explain it are not fully elucidated. Recently, new evidence
is emerging about some changes induced by radiation at
a molecular level, which may provoke a type of cell death
highly immunogenic [85]. Outside the ﬁeld of treatment,
radiation therapy can activate cells of the immune system to
produce proinﬂammatory mediators of genomic instability
[86]. Curiously, outcome of the inﬂammatory response
triggered by radiation can be beneﬁcial or detrimental
depending upon the context, which is related with the
type of macrophages activated (M1-proinﬂammatory or
M2-woundhealing) [87]. Moreover, ionising radiation has
diﬀerent immune eﬀects regarding the dose administered,
so in the case of low doses, the ﬁnal eﬀect is mostly
protumorigenic [88]. On the contrary, at higher doses
with cytotoxic activity, cell death may induce tumoral
neoantigens which can be embraced by dendritic cells, and
thus activate an eﬀective adaptive immune response [89].
As with anthracyclines, the two critical mediators of this
process seem to be translocation of calreticulin to the cell
surface and release of HMGB1 by the dying cells [85]
(Figure 1).Bothofthemtriggerdangersignalswhichactivate
immune mechanisms. In addition, surviving cancer cells
after radiation show increased expression of death receptors,
adhesionmolecules(ICAM-1),andmajorhistocompatibility
complexclassI(MHC-I),whichactivateAPCs[90,91].Once
APCs are activated, essentially dendritic cells (DCs), they
migrate to the tumor-draining lymph nodes, where na¨ ıve
T cells can be activated through interaction with tumor-
derived antigens presented by DCs. Preclinical studies have
also revealed that irradiation of the tumour site may induce
release of chemotactic cytokines, that regulate the transit of
leukocytes,especiallyeﬀectorTcells,frombloodintotumors
[92].
Sequence of immune events generated by radiotherapy is
critically important, since radiation of loco-regional lymph
nodes, which is a common procedure in daily practice, may
alter and disrupt the possibility of an eﬀective immune
response by depleting na¨ ıve T cells.
Immunogenicity of radiation therapy opens a new
window of clinical research. Theoretically, molecules like
anti-CTLA4 monoclonal antibodies, or costimulators such
as GM-CSF, Interferons, or IL-2, may serve as boosters,
amplifying immune eﬀectors triggered by radiotherapy.
So, if these new concepts are ﬁnally conﬁrmed in the
clinical setting, it will probably translate into a new way of
administering radiotherapy in the coming future.
5.3. Passive Immunotherapy: The Rituximab Era. More than
any other discovery, widespread use of monoclonal anti-
bodies (mAbs) in daily practice has dramatically improved
clinical results in terms of disease-free survival and overall
survival in many types of lymphomas. This is especially true
for rituximab, a chimeric monoclonal antibody targeting
the CD20 antigen found on both normal B cells and on
most low-grade and some high grade B-cell lymphomas
[93]. It is eﬀective as a single agent in induction and
maintenance therapy, though it is primarily used in com-
bination with standard chemotherapies in the treatment of
patients with non-Hodgkin’s B-cell lymphomas and chronic
lymphocytic leukemia [93]. Although its mechanisms of
action are not fully elucidated, rituximab can induce killing10 Journal of Biomedicine and Biotechnology
of CD20+ cells (95% of malignant B lymphocytes) via
multiple mechanisms. Direct eﬀects of rituximab encompass
complement-dependent cytotoxicy (CDC) and antibody-
dependent cell-mediated cytotoxicity (ADCC), which are
retained as the major mechanisms of action of rituximab
on B-cell lymphomas. The indirect eﬀects include structural
changes, B-cell apoptosis, and sensitization of cancer cells to
chemotherapy [83, 93].
The complement system can trigger three protease cas-
cades known as the classical, mannose binding lectin (MBL)
and alternative pathways. All three pathways converge at the
C3 and C5 levels, leading to the formation of a membrane
attack complex (MAC) that, if remains open, will directly
induce targeted cell lysis by osmotic mechanisms [94].
Speciﬁcally, rituximab activates the classical complement
cascade by interacting with C1q through its Fc region,
exposed after binding with CD20 on the B-cell surface [95],
forming MACs and subsequent cytolysis. Along with CDC,
rituximab-mediated ADCC is important for the elimination
of malignant B lymphocytes. ADCC triggers tumor cell
killing through interaction between the Fc region of CD20
binding rituximab and FcγRs. The ﬁnal eﬀect is releasing
of inﬂammatory and cytotoxic immune modulators, which
lead to phagocytosis of targeted cancer cells by mono-
cytes/macrophages and granulocytes/neutrophils, or lysis
mediated by NK cells using the granzyme-perforin system
[83, 96, 97]. Some cytokines may aid ADCC to enhance
cytotoxicity and avoid antibody-targeted tumor resistance
to innate immune cells. Again, GM-CSF has demonstrated
in vitro enhancement of cytotoxicity upon lymphoma cells
through upregulation of monocyte FcγRs [98]. Interleukin-
2 (IL-2) activates selective immune eﬀector cell responses
associated with antitumor activity, since IL-2-activated NK
cells strongly enhance activity of rituximab through ADCC
in primary B-cell NHL [99]. Moreover, IL-2 acts as a
chemokine,inducingactivationandtraﬃcofmonocyt esand
NK cells to tumors. Other cytokines as IL-12 also synergize
the rituximab eﬀect by upregulating γ-interferon and other
immune mediators, increasing NK cell lytic activity in vitro
[100].
CDC-resistant cells may be sensitive to ADCC, and the
sameoccurswithADCC-resistantcells,thatcanbedestroyed
by CDC activation [83]. Nowadays, it is widely accepted
that ADCC and CDC, the main mechanisms of action
of rituximab against lymphoid cells, act synergistically by
enhancing cytotoxicity in cancer cells through the ability of
complementtopromoteinﬂammationandinduceactivation
of innate immune eﬀectors.
Besidesthepureimmunogeniceﬀectsofrituximab,other
cytotoxic eﬀects have been studied, in particular apopto-
sis induction and direct growth arrest. CD-20-rituximab
crosstalk can redistribute lipid grafts of the cytoplasmic
membrane and subsequently transactivate the Src family
tyrosine kinase and the Fas-pathway, which results in initia-
tion of downstream signaling pathways leading to a caspase-
dependent apoptosis [18, 35, 101]. Moreover, rituximab
downregulates the p38 mitogen-activated protein kinase
(MAPK), nuclear factor (NF)-κβ, ERK-1/2, and Akt survival
pathways, thus inhibiting the expression of antiapoptotic
gene products (Bcl-2/Bcl-xL, and others) [102, 103]. Ritux-
imab also induces caspase-independent apoptosis, through
mechanisms still under investigation [104].
Inhibition of antiapoptosis related pathways sensitizes B-
cell NHL to undergo apoptosis and facilitates the proapop-
totic eﬀect induced by chemotherapy [105, 106]. The com-
bination of rituximab and CHOP chemotherapy (cyclophos-
phamide, doxorubicin, vincristine, and prednisone) is prov-
ing a highly eﬀective combination in the treatment of NHL
[93], with better clinical results of each treatment modality
alone. It seems that synergism of this chemoimmunotherapy
schedule relies, at least in part, in chemosensitization of
drug-resistant NHL cells mediated by rituximab via selective
downregulation of antiapoptotic factors through the type
II mitochondrial apoptotic pathway [105, 106]. Moreover,
new concepts about immunogenic apoptosis induced by
chemotherapy may also contribute to explain the success of
chemoimmunotherapy combinations.
6. Vaccines in Lymphoproliferative
Diseases
Concept of vaccination is based on the fact that deliberate
exposure to a harmless version of a pathogen generates
memory cells, but not the pathologic sequelae of the
harmful agent itself. In this way, the immune system is
primed to mount a secondary immune response with strong
and immediate protection against a new encounter with
the pathogen in the future [107]. Active immunotherapy
has been traditionally considered a promising approach in
lymphoproliferative diseases, especially in low-grade lym-
phomas. In this sense, follicular lymphomas have demon-
strated a high sensitivity to passive immunotherapy with
Rituximab and Interferons, either alone or combined with
chemotherapy [93]. Also, the indolent course of these dis-
eases, with prolonged spontaneous remissions in up to 23%
ofpatients,seemstobeascribedtoimmuneregulation[108].
Finally, survival of patients with FL appears to correlate with
gene expression signatures of tumor inﬁltrating lymphocytes
(TILs) [109].
Vaccine strategies targeting LF have largely focused on
using the tumor immunoglobulin molecule expressed on
the surface of malignant B cells as an antigen. Antibodies
can be produced as circulating or stationary molecules. The
latter type has a hydrophobic transmembrane sequence that
anchors the molecule in the B-cell membrane, where it
functions as the B-cell receptor. Antibodies consist of two
identical heavy chains and two identical light chains that
are held together by disulﬁde bonds. The variable regions
of the heavy and light chains of the tumor immunoglobulin
contain unique determinants known as idiotype (Id) that are
acollectionofantigenicdeterminantsselectivelyexpressedin
tumor cells and serve as tumor-speciﬁc antigens [110, 111].
Thus, idiotype vaccination can potentially induce eﬀective
polyclonal antibody and T-cell responses against malignant
clonal B cells.
Induction of clinically relevant tumour-speciﬁc immu-
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burden [112]. Therefore, probably the best clinical setting
for optimizing immunogenicity and achieving meaning-
ful clinical results comes after a complete response after
antineoplastic treatment. This is consistent with the way
vaccines work in infectious diseases, without the harmful
agent present at vaccination. Preclinical studies revealed that
the tumour-speciﬁc Id is a weak self-antigen [110, 111]. To
enhance immunogenicity, Id vaccine formulations require
conjugation to a strongly immunogenic carrier protein, such
as keyhole-limpet hemocyanin (KLH) [110]. In addition,
using an immunological adjuvant as GM-CSF facilitates
activation and recruitment of mature dendritic cells and
induction of tumor-speciﬁc CD8+ T cells [111]. Thus,
most of the following clinical trials use KLH+ GM-CSF to
overcome immune tolerance.
6.1. Clinical Trials with Idiotype Vaccines. Kwak et al. con-
ducted the ﬁrst study of Id vaccination in humans [113].
It was a pilot study in which 41 FL patients, in complete
response or minimal residual disease after chemotherapy,
were immunized with subcutaneous injections of autolo-
gous puriﬁed tumor-derived immunoglobulin conjugated
to KLH along with a standard emulsion adjuvant (Syn-
tex adjuvant formulation 1). Results were successful in
terms of biological eﬃcacy, with a demonstrated 41% of
speciﬁc anti-Id antibody, and clinical eﬃcacy with 17%
of cellular proliferative responses [113]. These promising
data led the Biological Resources Branch, Development
Therapeutics Program of the National Cancer Institute to
initiate phase 2 trials to conﬁrm safety, clinical eﬃcacy, and
good manufacturing practices (GMP) in order to start an
eventual commercialization [114, 115]. Most phase 2 studies
conﬁrmed that vaccines were well tolerated and induced
humoral and cellular immune responses with some clinical
eﬀects (clinical and molecular remissions). Results of phase
1 and 2 trials also suggested that biological and clinical
eﬃcacy may induce a clinical beneﬁt, which is the capacity
to inﬂuence on disease-free and overall survival. Inog´ es
and coworkers showed that patients with FL in second CR
after chemotherapy (not containing Rituximab) and being
successfully vaccinated in biological terms had longer CR
(more than 13 months) than the duration of the same
patient’s ﬁrst CR obtained with standard chemotherapy with
or without Rituximab [116]. These data, though achieved
in a limited number of patients, are critically important
because they suggest once again that the best clinical setting
toemployvaccinationiswhenthereisminimalornoresidual
disease[116].Hence,theseencouragingresultsachievedwith
the Id-KLH+ GM-CSF led to the initiation of three phase
3 trials to clarify its eventual clinical beneﬁt in FL patients
(Table 2).
6.2. Phase 3 Trials of Idiotype Vaccines. (i) First study
sponsored by Genitope included FL patients treated with
8 cycles of ﬁrst line CT with CVP schedule. Patients who
achieved a complete or partial response were randomized in
a 2:1 fashion to seven Id vaccine doses or a control arm with
KLH and GM-CSF. Finally 192 patients were vaccinated and
95 received control treatment. Regarding the main endpoint,
statisticalsigniﬁcancewasnotfoundintermsofprogression-
freesurvivalamongbotharms.However,itwasobservedthat
patients failing to mount an Id-speciﬁc humoral response
had signiﬁcantly worse results [117, 118].
(ii) Recently, Freedman et al. communicated the ﬁnal
results of another phase 3 trial sponsored by Favrille’s in
which patients treated with four doses of Rituximab who
entered in CR, PR, or SD were randomized to an Id vaccine
group (n = 174 patients) and a control group treated with
GM-CSF (n = 175 patients). This trial not only failed in
showinga better disease-freesurvivalforvaccinatedpatients,
but even demonstrated a statistically signiﬁcant diﬀerence
in favour of the control group treated with GM-CSF
[119].
(iii) In the 2009 American Society of Clinical Oncology
(ASCO) Annual Meeting, Schuster et al. presented phase
3 results on vaccine BiovaxID [120]. This trial, sponsored
by Biovest, included patients in CR or CR unconﬁrmed
after 6 cycles of CT with PACE or Rituximab plus CHOP.
Again, randomization was done in two groups, Id vaccine
(experimental) and KLH plus GM-CSF (control). Main
objective was disease-free survival. Unfortunately, this study
was halted in April 2008 with only 31,2% of patients
included, owed to rituximab irruption and dominance in
FL guidelines and clinical trials. Of 177 patients included
in this trial, 60 relapsed while waiting for their vaccine,
so conclusions were drawn from only 117 patients, 76 in
the experimental and 41 in the control group. Median
survival was statistically signiﬁcant favouring treatment arm
(44,2 versus 30,6 months; P = .047 ) and the main
endpoint showed a 13,6-month increase in median disease-
f r e es u r v i v a lf o rI dv a c c i n eg r o u p[ 120].
6.3. Pitfalls and Clues in Vaccine Development. Though
soluble protein idiotypic vaccination has provided proof of
principle of biological and clinical eﬃcacy, and even clinical
beneﬁt in some small clinical studies in FL, results of the
three phase 3 trials mentioned above are disappointing and
failed. However, there are many circumstances that may alter
ﬁnal results of these randomized trials.
(i) Two of the trials included patients irrespective of the
quality of the response after CT. As suggested in preclinical
models, disease’s situation at vaccination seems to be crucial.
When there is a sizable tumour burden, vaccines are less
likely to be eﬀective maybe because, among other mech-
anisms, remaining malignant cells still have the ability to
secrete cytokines to evade immune recognition. Accordingly,
it must be underscored that better clinical results have been
obtainedinclinicaltrialswhereaCRwaspreviouslyachieved
[114].
(ii) The Favrille’s phase 3 trial employed four doses
of Rituximab before vaccination [119]. Nowadays, in daily
clinical practice, it is preferred using chemoimmunotherapy
schedules at ﬁrst line in ﬁt patients. Hence, four doses of
Rituximab may be considered as a suboptimal schedule with
few complete responses. Besides this, Rituximab causes B cell
depletion in normal and malignant cells, hence interfering
in the initiation of humoral response. Final results of this12 Journal of Biomedicine and Biotechnology
Table 2: Phase 3 trials of idiotype vaccines.
Author/Sponsor Idiotype Comparison Pretreatment Patient status
prevaccination End Point Results
Levy et al. [118]
Genitope Recombinant 2/1 randomization in
ﬁrst line 8 cycles of CVP First CR or PR PFS P = n.s
Freedman et al.
[119]F a v r i l l e Recombinant 2/1 randomization in
ﬁrst line 4 doses of Rituximab First CR, PR or SD TTP P = n.s
Schuster et al.
[120]B i o v e s t From hybridoma 2/1 randomization in
ﬁrst line 6c y c l e so fP A C Eo rC H O P - R F i r s rC Ro rC R u D F S P = .045
phase III trial suggest poorer results for the experimental
arm and probably this is the consequence of an early
vaccination, before B-cell counts after rituximab treatment
were recovered.
However, there is still scarce evidence in vaccination
after rituximab-containing immunochemotherapy sched-
ules. Neelapu et al. [121] communicated data of a pilot
trial in 26 patients with mantle cell lymphoma treated with
EPOCH-R, followed 12 weeks later with ﬁve monthly vac-
cinations of autologous tumor-derived Id-KLH+GM-CSF.
As expected, after chemoimmunotherapy, peripheral blood
B cells were completely depleted in all patients. Recovery
was detected at 6 months, returning to baseline levels at 12
months. CD4+ T cell counts decreased only slightly after CT
and recovered 3 months later, by the start of vaccination.
CD8+ T cell counts did not change substantially. Curiously,
after rituximab administration, antibody responses against
KLH and Id were detected in 74% (17 out of 23) and 30%
(7 out 23) of patients, respectively. Humoral responses were
delayed and correlated with the recovery of B cells following
theadministrationofrituximab,especiallyafterthefourthor
ﬁfth vaccination.
The results of this pilot study are extremely important,
because it demonstrates that vaccination after rituximab
treatment is feasible and can induce delayed humoral
responses. Taking into account that Id vaccine production
takes some months, it would be interesting to design clinical
trialsinwhichId-vaccinewasadministeredbetween6and12
months after a chemoimmunotherapy schedule containing
rituximab.
(iii) Control group in the three phase 3 trials used
KLH+GM-CSF or GM-CSF. It is uncertain whether these
compounds may induce an immune response against lym-
phoid cells by themselves. In particular, GM-CSF is a
cytokine with highly immunogenic properties that has even
demonstrated clinical eﬃcacy in the clinical setting in FL, in
combination with Rituximab, and in other solid neoplasms
[122]. So, it is arguable if KLH+GM-CSF or GM-CSF alone
represents an ideal control group with neutral immune
eﬀects.
(iv) Follicular lymphoma is such a heterogenic disease
with a diﬀerent and unpredictable evolution. Moreover,
host’s immune response to vaccines is also heterogeneous
in every single patient. Therefore, there are many sources of
uncontrollable variability that make idiotypic vaccination in
FL such a diﬃcult strategy to reach success in randomized
clinical trials, where the methodology remains rigorously
dictated by statistics and clinical beneﬁt in the overall
population.
(v) As previously mentioned, several mechanisms may
explain the low clinical eﬀectiveness reported. One of the
main reasons lies in the inability of immune cells to
inﬁltrate and become activated after an encounter with
tumor antigen in vivo. Moreover, it seems that tumors do
not express costimulatory molecules or produce the inﬂam-
matory microenvironment necessary to activate eﬀector cells
with the ability to eradicate tumors [123, 124]. Therefore,
the development of methods to activate antitumor immune
cells by stimulating APCs and generate long-term memory
cells, probably with the aid of costimulators, is one of
the future challenges for deﬁnitively integrating tumor
vaccines into the antineoplastic arsenal. In this sense, GM-
CSF has demonstrated clinical activity when used alone
[125] (melanoma) and in combination with other agents
(follicular lymphoma, colorectal and breast cancer [82, 126,
127]). Among these protocols, GM-CSF administration is
prolonged, ranging from 5 to 14 days, yet in vaccine trials
GM-CSF is commonly used in a short course of three
or four doses. So, safety and eﬃcacy data encourage the
prolonged administration of maintenance boosters (GM-
CSF, Interleukin-2, etc.), especially once there is biological
evidence of an immune response successfully triggered.
(vi) Regardless of the method used, Id vaccine pro-
duction is expensive and time consuming. In fact, the
NCI/Biovest study loosed more than 30% of patients
included because of a relapse while waiting for the vaccine
production. This is especially worrying because it predicts
serious diﬃculties in an eventual extensive clinical use.
Other sources of vaccination are under development with
membrane proteoliposomes, or tumor cell-based vaccines
transduced with GM-CSF, CD40-activated or HSP-96 [111].
These new formulations are under clinical investigation,
mostly in phase 1 trials and have the advantage of targeting
multiple tumor antigens with a shorter production time.
(vii) Therapeutic armamentarium in LF is changing,
and knowledge of the immune eﬀects of the new therapies
employed may be of critical importance for clinical trials
with Id-vaccines. Recently, Yttrium-90 Tositumomab Tiux-
etan (ZevalinR) has been approved by the FDA in ﬁrst line
of LF, as consolidation after CT [128]. ZevalinR is a CD-20-
directed radiotherapeutic antibody with several mechanisms
of action. In addition, in the 2009 annual meeting ofJournal of Biomedicine and Biotechnology 13
the American Society of Hematology (ASH), results of a
phase III trial in low-grade lymphomas, comparing CHOP-
RandBendamustine-R,havebeencommunicated,providing
betterprogression-freesurvival(medianPFS54,9versus34,8
months; HR 0.57, P = .00012 ) and a better toxicity proﬁle
for the experimental arm [129]. These data could oust the
standard CHOP-R regimen in brief, so anthracyclines could
be out of ﬁrst line treatment in the coming future.
Eventhoughclinicalresultsinmanytypesoflymphomas,
including LF, that have improved over the years owed
to introduction of rituximab and chemoimmunotherapy
schedules, there is still room for improvement; yet many
patients relapse and ﬁnally die as a consequence of their
disease.Thus,onceconﬁrmedproofofprincipleofbiological
and clinical eﬃcacy of vaccine-therapy, these results might
not be overlooked nor neglected by physicians, since it may
translate into a prolonged disease-free survival, and eventu-
ally the recovery of some LF populations. Although history
of vaccines in Oncology has been extremely disappointing,
reminding the myth of Minotaurus, with every little step
forward followed by a new frustration, new insights into this
strategy may hopefully obtain better and surprising results,
and so ﬁnding out the Ariadne’s thread which eventually
leads to see the end of this complex and challenging
labyrinth.
7. Conclusions andFinalRemarks
Tumorigenesis is a multistep process leading to the progres-
sivetransformationofnormalhumancellsintohighlymalig-
nant derivatives. Thus, mechanisms of oncological diseases
are extremely complex, with several alterations at multiple
sites. Hanahan and Weinberg, in an eﬀort to synthesize the
huge body of knowledge in cancer research, postulated six
essential alterations in cell physiology [130]. Among them,
the insensitivity to antigrowth signals, evasion of apoptosis,
sustained angiogenesis, and tissue invasion and metasta-
sis seem to be intrinsically related to microenvironment
dysregulations. Lymphomas constitute an excellent model
for microenvironment translational research. These tumors
might be considered as a functional tissue immunologically
mediated and formed by a complex tissue network in which
the imbalance of homeostasis between the host immune
system,malignantcells,andallothercomponentsoftumoral
stroma determine proliferation, invasion, angiogenesis, and
remodelling of extracellular matrix and metastasis. More-
over, the distinctive proﬁle of immune cells in the sur-
rounding stroma leads to a wide repertoire of speciﬁc
cell subpopulations which constitute the speciﬁc tumor
microenvironment of each lymphoproliferative syndrome.
In the last few years, the critical importance of these ﬁndings
and correlation with prognosis and clinical results has been
recognized.
Recent evidence has emerged that confers new prop-
erties to antineoplastic treatments against lymphomas, in
relation with microenvironment changes. This is the case
of some chemotherapeutics like anthracyclines or radio-
therapy that may induce tumoral destruction with the
ability of improving cancer cell recognition by the immune
system, and thus enhancing the possibility of a successful
immune response. In addition, these “new discoveries” in
themechanismsofactionofclassicantineoplastictreatments
might be the basis of the synergism of the new combined
chemoimmunotherapy strategies in lymphomas that include
passive immunotherapy with the monoclonal antibody Rit-
uximab. Finally, active immunotherapy with anti-idiotype
vaccines, though still far from daily practice integration,
has demonstrated clinical eﬃcacy in some subpopulations
of patients. Fine tune approaches in vaccine development
and a better design of vaccine clinical trials are needed
to deﬁnitely elucidate the role of active immunotherapy in
lymphoproliferative syndromes.
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